Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience's stock price increased significantly, with an 859.29% increase from April 7, 2025, to April 2, 2026. The company announced a $120 million private placement financing in March 2026. Topline data from the Phase 2 study of ALTO-101 did not achieve statistical significance on its primary endpoint. The company reported its full-year 2025 financial results and Q3 2025 financial results, highlighting pipeline progress. A U.S. patent was issued for methods of treating depression with ALTO-207. The company has a consensus rating of 'Moderate Buy' from analysts, with an average price target of $35.14. The next earnings report is expected around May 20, 2026.

Alto Neuroscience, Inc. does not exhibit traditional demand seasonality for its products and services. Demand for its product candidates will be driven by medical need, treatment efficacy, regulatory approvals, and market adoption rather than seasonal fluctuations. The company's revenue is currently 0 USD, as it is in the development phase.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on personalized and effective treatment options for neuropsychiatric disorders. The company operates in the Biotechnology industry and uses its Precision Psychiatry Platform to identify brain-based biomarkers to predict patient response to its product candidates. Its pipeline includes clinical-stage assets like ALTO-100 for bipolar depression, ALTO-300 for major depressive disorder, ALTO-101 for cognitive impairment associated with schizophrenia, ALTO-203 for MDD with anhedonia, ALTO-202 for MDD, ALTO-207 for treatment-resistant depression, and ALTO-208 for Parkinson's disease.

Alto Neuroscience, Inc. is headquartered in Mountain View, California, and operates within the United States.

Alto Neuroscience's brand reputation is generally positive, driven by scientific advancements and positive analyst sentiment. The company has a consensus 'Moderate Buy' rating from Wall Street analysts. Pipeline advancements, financial milestones like the $120 million private placement, and the focus on precision psychiatry contribute to its reputation. There is no readily available information indicating specific events that have negatively impacted Alto Neuroscience, Inc.'s reputation in the past year.

Alto Neuroscience, Inc. has significant institutional ownership, accounting for approximately 76.65% of the company. Individual insiders hold about 21.03%, and retail investors hold 2.31%. Major institutional and individual owners include Falcon Edge Capital, LP, Vestal Point Capital, LP, Commodore Capital Lp, Perceptive Advisors Llc, Point72 Asset Management, L.P., Armistice Capital, Llc, Vanguard Group Inc, Franklin Resources Inc, Vivo Capital, LLC, 72 Investment Holdings, LLC, Alpha Wave Global LP, Amit Etkin, D. E. Shaw & Co., Inc., Cantor Fitzgerald, L. P., State Street Corp., Lightswitch Capital Management, L.P., and BlackRock, Inc. Insider selling has been observed, and shareholders have experienced dilution.